Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

This is a phase 2, open-label, single-arm trial designed to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with pembrolizumab following disease progression after two prior lines of standard therapy in unresectable metastatic stage IV breast cancer

NCT Number	NCT04990921
Lead Sponsor	University of Louisville Collaborators: James Graham Brown Cancer Center
Conditions	Metastatic Breast Cancer
Enrollment	15 participants
Start Date	2021-09-02
Primary Completion	2031-07-01 (estimated)
Study Completion	2031-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-02-20